Skip to main content
. 2019 Sep 4;33(11):2168–2178. doi: 10.1111/jdv.15793

Figure 2.

Figure 2

Main Efficacy outcomes over 52 weeks. (a) Achievement of Total‐Fingernail mNAPSI 75 (Continuous‐ADA Population). (b) Achievement of PGA‐F 0/1 with ≥2 Grades Improvement from BL (Continuous‐ADA Population). (c) Achievement of Total‐Fingernail mNAPSI 75 (OLE). (d) Achievement of PGA‐F 0/1 with ≥2 Grades Improvement from BL (OLE). Missing data were handled by multiple imputation. Abbreviations: ADA, adalimumab; BL, baseline; mNAPSI, modified Nail Psoriasis Severity Index; NRI, non‐responder imputation; OLE, open‐label extension; pbo, placebo; PGA‐F, Physician's Global Assessment of Fingernail Psoriasis; W, week.